CA: A Cancer Journal for Clinicians
ABSTRACT Tumor-agnostic therapies represent a paradigm shift in oncology by altering the traditional means of characterizing tumors based on their origin or location. Instead, they zero in on specific genetic anomalies responsible for fueling malignant growth. The watershed moment for tumor-agnostic therapies arrived in 2017, with the US Food and Drug...
CA: A Cancer Journal for Clinicians, Volume 74, Issue 3, Page 207-209, May/June 2024.
CA: A Cancer Journal for Clinicians, Volume 74, Issue 3, Page 210-212, May/June 2024.
Abstract Cancer mortality rates have declined during the last 28 years, but that process is not equitably shared. Disparities in cancer outcomes by race, ethnicity, socioeconomic status, sexual orientation and gender identity, and geographic location persist across the cancer care continuum. Consequently, community outreach and engagement (COE) efforts...
Abstract The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to...
Construisez votre propre fil d'actualité
Prêt à tenter le coup ?
Commencer un essai de 14 jours, aucune carte de crédit n'est requise.